Compare SiTime Corporation (SITM) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SiTime Corporation vs Zimmer Biomet Holdings Inc — how do they compare? SiTime Corporation trades at $609.46 (market cap $19.42B), while Zimmer Biomet Holdings Inc trades at $89.12 (market cap $16.95B). The key difference: SiTime Corporation and Zimmer Biomet Holdings Inc are close in size by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while SiTime Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold SiTime Corporation for 18 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SITM | ZBH | |
|---|---|---|
Market Cap | $19.42B | $16.95B |
Volume | 360,307 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $901.60 | $103.98 |
52-Week Low | $252.76 | $79.58 |
Typical Hold Time | 18 Days | 89 Days |
Enterprise Value | $18.82B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SITM is trading at $665.16, down 6.46% over the past 24 hours, with a bullish technical signal supported by moving averages. The company shows strong revenue growth momentum with Q2 2026 revenue surging 126.5% year-over-year to $157.43 million, marking its first GAAP profit. Analyst consensus remains strongly positive with 9 buy ratings and a $751.43 price target representing 13% upside potential. Recent institutional activity includes California State Teachers Retirement System increasing its stake by 73,098.9% during the latest quarter.
The outlook remains positive driven by AI infrastructure demand and the Renesas acquisition, though valuation metrics appear elevated with P/E at 1,076 and P/S at 36.9. Key risks include execution challenges in scaling operations and potential market volatility. The stock's current position near recent highs suggests cautious optimism is warranted despite strong growth fundamentals.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
